GSK receives positive opinions in EU for Votrient and Tyverb
19 February 2010
Malini Guha
Please Login to read the full article.
19 February 2010
Malini Guha
The EU's CHMP has recommended granting conditional approval to GlaxoSmithKline's Votrient (pazopanib) in advanced kidney cancer and an extension of Tyverb's (lapatinib) indication in advanced breast cancer.
Votrient's conditional approval recommendation is for the first-line treatment of advanced...
Please Login to read the full article.
RELATED CONTENT
NEWS
- AVEO/Astellas 2012 filing for tivozanib as it beats Nexavar in Ph III kidney cancer trial
- ODAC backs Pfizer kidney cancer drug as second-line treatment
- FDA gives thumbs up to Pfizer kidney cancer drug
- GSK expands tiered pricing approach in India with Votrient and Revolade launches
ANALYSIS
Other Informa Analysis
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
